Creatinine Reduction Ratio and 24-Hour Creatinine Excretion on Posttransplant Day Two
- 1 June 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 13 (6) , 1645-1649
- https://doi.org/10.1097/01.asn.0000014253.40506.f6
Abstract
To devise objective criteria for early diagnosis of delayed graft function (DGF), 59 adult living donor kidney transplants with immediate graft function (IGF) and 51 cadaveric kidney transplants were investigated for creatinine reduction ratio (CRR2) from posttransplant day 1 to day 2 and 24-h urine creatinine excretion (UC2) on day 2. The mean CRR2 in living donor transplants was 53% (SD ± 11); the distribution of CRR2 was gaussian, and all of them had UC2 >1000 mg. Criteria for DGF were developed on the basis of living donor transplant: CRR2 ≤30% (2SD below 53%) ± UC2 ≤1000 mg. Overall, 24 cadaver transplant recipients (47%) developed DGF (CRR2 ≤30%); 13 patients (25%) had mild DGF (UC2 >1000 mg), and the remaining 11 (22%) had severe DGF (UC2 ≤1000 mg). All the patients with severe DGF had a measured creatinine clearance <25 ml/min on day 7, and 8 of 11 were dialyzed within the first week of transplantation. Patients with IGF and mild DGF had a creatinine clearance of ≥25 ml/min on or before day 7, and none of them were dialyzed. Calcineurin inhibitors were avoided or delayed in five patients with mild DGF and all patients with severe DGF. In conclusion, diagnosing DGF within 48-h after transplantation is simple and may be valuable in the management of these patients.Keywords
This publication has 8 references indexed in Scilit:
- A calcineurin inhibitor‐sparing regimen with sirolimus, mycophenolate mofetil, and anti‐CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft functionClinical Transplantation, 2000
- SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12Transplantation, 2000
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- DELAYED GRAFT FUNCTION DOES NOT REDUCE THE SURVIVAL OF RENAL TRANSPLANT ALLOGRAFTSTransplantation, 1998
- DELAYED GRAFT FUNCTION: RISK FACTORS AND IMPLICATIONS FOR RENAL ALLOGRAFT SURVIVAL1Transplantation, 1997
- Delayed function reduces renal allograft survival independent of acute rejectionNephrology Dialysis Transplantation, 1996
- DELAYED GRAFT FUNCTION, ACUTE REJECTION, AND OUTCOME AFTER CADAVER RENAL TRANSPLANTATIONTransplantation, 1995
- THE EFFECTS OF DELAYED FUNCTION OF RECIPIENTS OF CADAVER RENAL ALLOGRAFTSTransplantation, 1986